Last Updated : November 5, 2024
Details
FilesGeneric Name:
clindamycin plus benzoyl peroxide and adapalene
Project Status:
Active
Therapeutic Area:
acne vulgaris
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cabtreo
Project Line:
Reimbursement Review
Project Number:
SR0794-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 29-Jan-24 |
|---|---|
| Call for patient/clinician input closed | 25-Mar-24 |
| Clarification: - Patient input submission received from Acne and Rosacea Society of Canada (ARSC) and Canadian Skin Patient Alliance (CSPA) | |
| Submission received | 08-Mar-24 |
| Submission accepted | 26-Mar-24 |
| Clarification: - Submission was not accepted for review on 25 Mar 2024 | |
| Review initiated | 27-Mar-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 20-Jun-24 |
| Deadline for sponsors comments | 03-Jul-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 16-Aug-24 |
| Expert committee meeting (initial) | 28-Aug-24 |
| Draft recommendation issued to sponsor | 11-Sep-24 |
| Draft recommendation posted for stakeholder feedback | 19-Sep-24 |
| End of feedback period | 04-Oct-24 |
| Final recommendation issued to sponsor and drug plans | 18-Oct-24 |
| Final recommendation posted | 05-Nov-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 01-Nov-24 |
| CADTH review report(s) posted | - |
Files
Last Updated : November 5, 2024